Published in final edited form as:

Curr Osteoporos Rep. 2019 December ; 17(6): 395–404. doi:10.1007/s11914-019-00548-4.

Mechanisms of Immune Evasion and Bone Tissue Colonization that make *Staphylococcus aureus* the Primary Pathogen in Osteomyelitis

Gowrishankar Muthukrishnan^{1,2}, Elysia A. Masters^{1,3}, John L. Daiss^{1,2}, Edward M. Schwarz^{1,2,3}

¹Center for Musculoskeletal Research,

²Department of Orthopaedics,

³Department of Biomedical Engineering, University of Rochester Medical Center, Rochester, NY, USA

Abstract

PURPOSE OF REVIEW: *Staphylococcus aureus* is the primary pathogen responsible for osteomyelitis, which remains a major healthcare burden. To understand its dominance, here we review the unique pathogenic mechanisms utilized by *S. aureus*, that enable it to cause incurable osteomyelitis.

RECENT FINDINGS: Using an arsenal of toxins and virulence proteins, *S. aureus* kills and usurps immune cells during infection, to produce non-neutralizing pathogenic antibodies that thwart adaptive immunity. *S. aureus* also has specific mechanisms for distinct biofilm formation on implants, necrotic bone tissue, bone marrow and within the osteocyte-lacuno canicular networks (OLCN) of live bone. In vitro studies have also demonstrated potential for intracellular colonization of osteocytes, osteoblasts and osteoclasts.

SUMMARY: *S. aureus* has evolved a multitude of virulence mechanisms to achieve life-long infection of bone, most notably colonization of OLCN. Targeting *S. aureus* proteins involved in these pathways could provide new targets for antibiotics and immunotherapies.

Keywords

Staphylococcus aureus; osteomyelitis; adaptive immunity; immune proteome; orthopaedic infections; canalicular invasion

Corresponding Author: Edward M. Schwarz, Ph.D., Burton Professor of Orthopaedics, Director of Center for Musculoskeletal Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 665, Rochester, NY 14642, Phone: (585) 275-3063, FAX: (585) 276-2177, Edward_schwarz@urmc.rochester.edu.

Conflict of Interest

EMS is a founder of Telephus Medical LLC (San Diego, CA). JLD is a co-founder of MicroB-plex, Inc. (Atlanta, GA.) and works there part-time. All other authors declare that they have no conflict of interest.

Introduction

Hard-to-treat, deep infections such as osteomyelitis remain a significant healthcare problem in the United States and around the world [1]. Even with major advances in surgical procedures, and novel antimicrobial therapies, the treatment failure rate remains high [2–4]. The cost to treat prosthetic joint associated osteomyelitis is projected to rise to \$1.62 billion a year by 2020 due to the aging population in the United States [1, 5, 6]. Unfortunately, there has been little or no reduction in infection-related outcomes in several decades as the current standard of care treatments, developed in the 1970s, are still being employed in the US hospitals [7*–9*].

Osteomyelitis, defined as an infection of the bone, can occur by: 1) the local spread of the bacteria from a contaminated bone to an adjacent uninfected bone, 2) contamination of the bone via the hematogenous route, and 3) bacterial invasion of the bone from an infected implant [10, 11]. There are five distinct classes of osteomyelitis. These include: 1) prosthetic joint infection (PJI), the post-operative infection that occurs after a prosthetic joint has been placed, typically in the knee or hip; 2) fracture-related infection (FRI), a common complication in trauma surgery where patients typically present with open fractures; 3) acute hematogenous osteomyelitis (AHO), that arises due to seeding bacteria circulating in blood to the long bones; 4) diabetic foot infections (DFI), frequently observed as a polymicrobial infection of a diabetic foot ulcer that spreads contiguously to the underlying bone; and 5) osteomyelitis of the spine (OMS), that usually occurs postoperatively [1, 10, 11, 12*, 13, 14].

The incidence rate of all classes of orthopaedic infections range from 0.1%–30%, and treatment can cost up to \$150,000 per patient in the US [7*]. The rate of PJI in primary arthroplasty remains between 1% and 2%, though re-infection rates remain far higher for these patients: 8% for hips and knees. Unfortunately, due to the aging population in the US, and the increased number of elective total knee and hip arthroplasties in the last two decades, the anticipated incidence rate of PJI will likely increase in the near future. Moreover, there is increasing incidence of arthroplasty procedures for other joints such as the ankle and shoulder, that could also affect the overall incidence of PJI [1, 6, 15]. The incidence rate for FRIs is much higher, from 10% to 50% depending on the fracture type [12, 16]. Typically, monomicrobial AHO represents about 20% of all osteomyelitis cases and is most prevalent in children and related to rapid bone growth; about 85% of AHO patients are under 17 years of age [17–19]. Recently, AHO rates have increased in adults due to secondary conditions such as bacteremia induced by intravenous drug abuse associated with the opioid abuse crisis in the US [20, 21]. Among the osteomyelitis patients, DFI patients have the highest mortality risk. Their five-year mortality rate is reported to be 50%, equal to that of the most life-threatening cancers [22]. Moreover, their quality of life is among the poorest of the osteomyelitis patients as two-thirds of lower extremity amputations are associated with DFI [13, 23, 24]. Finally, the post-operative occurrence rate of OMS is between 0.3 and 20%, a prevalence rate that is higher than all of the other classes of orthopaedic infections [14].

Most research on bone infections has centered on *Staphylococcus aureus* (*S. aureus*) due to its frequency, plasticity and resistance, and because it causes the majority of osteomyelitis cases. *S. aureus* is a gram-positive coccus, first isolated by Alexander Ogston from the pus of surgical wound infections in the 1880s. An astounding 50% of the prosthetic joint-related orthopaedic infections are caused by difficult-to-treat MRSA strains [15, 25–27]. It is a successful pathogen that has evolved to infect nearly every organ system of the human body through its vast immune evasion and persistence mechanisms. In the context of osteomyelitis, *S. aureus* harnesses these mechanisms to persist within various tissue types and in doing so, alters its state of growth to infect for years or even decades [28–31]. There is an urgent need to control *S. aureus* osteomyelitis. To achieve that goal, we need a better understanding of the intricate immune evasion mechanisms that the pathogen employs to successfully invade and thrive in the bone environment. In this review, we will summarize these mechanisms with a particular focus on the host's adaptive immunity and *S. aureus*'s mechanisms for circumventing it.

Adaptive immune responses in host defense to *S. aureus* osteomyelitis

Adaptive immunity against *S. aureus* osteomyelitis consists of cell-mediated immune responses dominated by T cells and humoral antibody responses mediated by B cells. Adaptive immune responses are triggered after a week of *S. aureus* infection. These typically occur after presentation of antigens to dendritic cells and subsequent activation of T cells. Our understanding of the role of T-cells in *S. aureus* infections have vastly improved over the past 20 years (reviewed elsewhere [32–34]). Activated T cells, subsequently activate B cells, that differentiate into plasma cells, the producers of antigen-specific antibodies. A portion of these activated B cells become memory cells, that can be recalled to produce antibodies during reinfections. Unfortunately, because *S. aureus* can cause persistent and chronic infections, such as osteomyelitis, adaptive memory responses are not entirely effective. In this review, we will focus on B cell response mechanisms and how *S. aureus* cleverly evades humoral immune responses during chronic osteomyelitis. Specifically, we will discuss how *S. aureus* manipulates B cell function and survival during infection. We will also discuss studies that focus on *S. aureus* humoral immune proteome, the sum of all the host's antibodies produced against the pathogen.

Manipulation of B cells by *S. aureus*

The ability of *S. aureus* to cause disease is largely attributed to the expression of its vast array of virulence factors including immunomodulatory proteins, adhesins, toxins, and superantigens, several of which have redundant functions. *S. aureus* manipulates B cell survival and function through the production of staphylococcal protein A (SpA), a sortase-anchored protein with very high affinity to human immunoglobulins. The immunomodulatory effects of SpA have been attributed to two distinct binding activities: association with 1) the Fc domains of most human IgG molecules and 2) the Fab domains of certain antibody variable region families [35–37]. During infection, SpA is released into host tissues where it binds to the Fc γ domain of IgG, blocking antibody-mediated phagocytosis. SpA is also capable of binding the Fab domains to crosslink the VH3 clan of IgM antibodies. This in turn, causes proliferative expansion of B cells, which ultimately leads to

their collapse by apoptosis [38, 39]. Interestingly, Pauli and colleagues demonstrated that activated B cells, during infection, elicit a highly limited response with a significant bias towards VH3 idiotype. They also found that maturing plasmablasts had high affinity to SpA [40]. Limiting the host's B cell response predominantly to a particular immunodominant antigen such as SpA is one-way *S. aureus* ensures that there is no protection or memory against other virulence proteins during a chronic infection like osteomyelitis. A recent study also demonstrated that SpA reduced the pool of bone marrow (BM)-resident long-lived plasma cells that are responsible for secreting protective antibodies [41]. Indeed, SpA variants that cannot bind to immunoglobulins demonstrated attenuated disease in a murine model of bacteremia. It was shown that the adaptive immune response in these mice produced antibodies against many antigens, that were protective against recurrent infections [42*, 40]. Currently, a non-toxogenic variant of SpA is being actively pursued as a passive and active vaccine candidate against *S. aureus* colonization and chronic infections [43–46].

To better understand the interaction of Staphylococci with human B-cells, Nygaard and colleagues, performed B-cell association studies with *S. aureus* and *S. epidermidis*. They observed that a significantly larger proportion of B cells associated with *S. epidermidis* than with *S. aureus* and the observed binding was mediated by abundant proteins in the complement cascade [47]. This study highlighted the importance of pathogen-produced virulence molecules for the inhibition of the complement pathway and complement-mediated opsonophagocytosis. Staphylococcal complement inhibitor (SCIN) and extracellular fibrinogen-binding protein (Efb) are secreted by *S. aureus* and inhibit the deposition of activated C3 and C4 derivatives on the bacteria's surface [48]. On a related note, we have demonstrated that anti-SCIN and anti-Efb IgG levels in human serum can be useful diagnostic markers to identify *S. aureus* osteomyelitis in patients [49**].

Humoral immune proteome of *S. aureus* during osteomyelitis

Due to life-long exposure to *S. aureus* through prior infections or asymptomatic colonization, anti-*S. aureus* antibodies are prevalent in all humans after only a few weeks of age [50–54]. The sum total of all of the host's antibodies against a particular pathogen is termed the “humoral immune proteome”. Unfortunately, as mentioned, the presence of these pre-existing antibodies does not confer protection against *S. aureus* reinfection or persistent infections [50–54]. This is because not all pre-existing antibodies are protective antibodies that can neutralize *S. aureus* virulence proteins, toxins and/or mediate phagocytic killing and clearance of the pathogen. In fact, there are cases where non-neutralizing or pathogenic antibodies can facilitate the growth and dissemination of *S. aureus*.

Even though the antibodies produced are limited in their host protection, the anti-*S. aureus* humoral immune response in physiologic and pathologic conditions can be a useful tool for the diagnosis of *S. aureus* infections, especially for deep infections such as osteomyelitis. These infections are difficult to identify, and patients typically present with non-specific symptoms such as pain, fever, and swelling of the joint. Utilizing a multi-antigen Luminex immunoassay, we defined the humoral immune proteome of patients with *S. aureus* osteomyelitis. Iron scavenging proteins (IsdA, IsdB), and cell wall enzyme bifunctional autolysin (amidase (Amd), and glucosaminidase (Gmd)) were the most immunodominant

antigens during *S. aureus* osteomyelitis [49]. Among these antigens, we observed that certain ones could be predictors of outcomes of *S. aureus* infections in patients. Specifically, higher serum anti-IsdA and anti-IsdB IgG levels correlated with increased mortality in patients, indicating their role as pathogenic antibodies, while anti-Gmd IgG levels correlated with protection against *S. aureus* osteomyelitis, identifying these as protective antibodies [55, 49]. Indeed, we predict morbid outcomes if antigens that elicit pathogenic antibodies would ever be used as potential vaccine candidates. A case in point was the Phase 2/3 clinical trial of an IsdB active vaccine (Merck's V710) [56]. This 8000-patient clinical trial was abruptly terminated because of a five-fold increase in patient mortality induced by multiple organ sepsis in the IsdB-vaccinated group. We hypothesize that non-neutralizing pathogenic IsdB antibodies, generated by vaccination, promoted *S. aureus* growth and dissemination into distal organs. In a murine model of *S. aureus* osteomyelitis, we observed that active and passive IsdB immunizations rendered mice more susceptible to multiple organ sepsis (Nishitani, Ishikawa, Schwarz (unpublished results)). In sharp contrast to non-neutralizing pathogenic IsdB antibodies, neutralizing anti-Gmd monoclonal antibody significantly reduced MRSA infection severity in a murine model of implant-associated osteomyelitis [57, 58*]. Our laboratory is currently pursuing anti-Gmd passive immunization strategies to prevent and treat *S. aureus* osteomyelitis. Assessment of neutralizing antibodies and humoral immune responses against acute *S. aureus* infections, such as bacteremia, skin and soft tissue infections, is being pursued by other investigators [59–61].

In addition to antibody-producing long-lived plasma cells, newly activated pathogen-specific B cells called circulating plasmablasts or antibody-secreting cells (ASC) are of key importance for protecting against *S. aureus* infections. These ASC are activated early in an infection and disseminate into the blood en route to other lymphoid tissues as long as the infecting pathogen remains active [62*–65]. It is unclear if these recently activated plasmablasts produce neutralizing or pathogenic antibodies. Nonetheless, the antibodies produced by these cells can be useful diagnostic and prognostic markers of ongoing bacterial and viral infections [66, 67, 63, 64, 68]. In a recent study involving chronic osteomyelitis in patients that were undergoing foot salvage therapy (FST) for diabetic foot infections (DFI), we demonstrated that antibodies secreted by plasmablasts can not only accurately diagnose ongoing infections, they can also track treatment responses and detect persistent or recurrent infections that are indiscernible in serum response [68**]. Thus, measuring the humoral immune proteome in a simple immunoassay could significantly change the way *S. aureus* osteomyelitis is diagnosed and treated.

Immune evasion strategies and *S. aureus* persistence in osteomyelitis

Bacterial infection of bone presents a unique set of immune challenges because of the different modes of colonization and persistence within the bone. Here we consider four immune mechanisms of *S. aureus* persistence in the context of osteomyelitis: 1) abscesses; 2) biofilms; 3) invasion of the osteocyte-lacuno canalicular network (OLCN) of bone; and 4) intracellular infection (Fig. 1). In the short term, bacteria can evade innate immune attack and survive within abscesses located in the bone marrow and the surrounding soft tissue. As acute bone infection progresses, the local tissue becomes devascularized and sequestered to

isolate the infected region from healthy tissue. The sequestered tissue becomes a haven for bacterial persistence in the form of biofilms and within the OLCN of bone. Finally, the possibility of intracellular infection has been investigated recently as an additional mechanism of persistence in osteomyelitis. Together, these adaptive defense mechanisms allow *S. aureus* to chronically infect bone despite all efforts of eradication.

Abscess Formation

Abscess formation is typically considered a host-induced mechanism of infection control initiated by innate immune cells to sequester infected tissue and associated pathogens. However, it is known that *S. aureus* manipulates the host response by deploying an array of virulence factors that trigger the formation of the multilayered structure of an abscess with protected bacterial cells at its core. Described as “a play in four acts” [69], *S. aureus* must first overcome innate immune defenses within the bloodstream, including phagocytes, complement and antimicrobial peptides (AMPs). This is accomplished via expression of microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) including clumping factor A (ClfA) [70], that facilitates binding to fibrin or fibrinogen and results in aggregation of *S. aureus* colonies that are resistant to phagocytosis [71].

In addition to cell-wall associated enzymes and binding molecules, *S. aureus* secretes proteins such as chemotaxis inhibitory protein of staphylococci (CHIPS) [72] and SCIN [73] to evade the early-stage acute immune response. Following distribution to various organ sites via the bloodstream, the pathogen recruits large numbers of neutrophils and other innate immune cells to the site of infection. The expression of proinflammatory iron scavenging proteins IsdB, IsdA and IsdH promotes the local secretion of inflammatory cytokines, triggering an influx of neutrophils [74, 75]. The third stage of staphylococcal abscess maturation involves the formation of a multi-layered structure of dead and live neutrophils around a central core of live *S. aureus* cells [76]. Expression of coagulase (Coa), as well as von Willebrand’s factor binding protein (vWFbp), are key to this stage of abscess maturation as they assist in the formation of a protective fibrin “pseudocapsule” [77]. Other genes required for abscess formation and maturation appear to be SpA and Emp since their mutants are unable to form proper abscesses [76]. The fourth and final stage of staphylococcal abscess maturation is steady persistence, followed by the ultimate bacterial egress and dissemination to new sites. It has been shown that *S. aureus* mutants lacking the immunomodulatory proteins Eap and Ess are deficient in abscess persistence, suggesting their involvement in prolonged survival within an abscess [78].

Staphylococcal abscesses during osteomyelitis are usually formed in the bone marrow space as well as in adjacent soft tissues [58, 79]. In a mouse model of implant-associated osteomyelitis, it was shown that diabetic obese mice had more severe infections with an increased number of bone abscesses relative to healthy control mice [80]. Further, *S. aureus* isolated from type-2-diabetic infections exhibited upregulation of genes associated with fibrin and fibrinogen binding [80].

Biofilm Formation

Staphylococcal biofilms formed on implanted materials and necrotic bone are the most recognized forms of *S. aureus* persistence in osteomyelitis. In orthopaedic infections, biofilms are presumed to be the leading cause of incurable, chronic infections [81–83]. The formation of a biofilm begins with the initial attachment of planktonic bacterial cells to a substrate. This attachment step is mediated by *S. aureus* MSCRAMMs that have the ability to bind a wide array of extracellular matrix proteins. The attachment of planktonic cells then triggers the synthesis of extracellular polymeric substances (EPS) including polysaccharides, proteins and nucleic acids. Together, these substances encase the bacterial cells, prevent immune cell attack, mediate adhesion, provide mechanical stability, and retain essential nutrients and enzymes [84].

When embedded within the protective EPS matrix, bacterial cells can survive drug dosing of up to 1000 times greater than their planktonic phenotype [85]. The elevated resistance to antibiotics in the biofilm phenotype is, in part, due to decreased drug diffusion from the exterior of the biofilm to the bacteria that are buried deeply within. Additionally, the effectiveness of antibiotics that successfully diffuse through the biofilm is diminished due to the altered metabolic phenotype of bacteria growing in biofilms, making them more resistant to drug treatments.

As the bacteria continue to divide within the biofilm, local nutrients become depleted, and additional survival strategies are deployed. First, some bacteria within the biofilm undergo phenotypic or genotypic changes that dramatically reduce their metabolic requirements [86, 87]. In doing so, a subpopulation of the bacteria shifts into a slow-growing persistent state. Because of these changes, the slow growing bacterial population is also more resistant to antibiotics that attack actively dividing bacteria [86, 87]. A second *S. aureus* survival strategy is the activation of the accessory gene regulator (*agr*) quorum sensing system [88]. The *agr* quorum sensing system is commonly considered to be the primary regulator of virulence factors in *S. aureus* as its activation triggers the expression of secreted toxins such as α -hemolysin (Hla) and the phenol soluble modulins (PSMs) [89]. Other virulence factors that play a critical role in biofilm formation during chronic osteomyelitis are discussed elsewhere [90, 91].

Unfortunately, to date, there is no standard method for *in vitro* biofilm growth, making comparison of results from lab-to-lab and hospital-to-hospital widely variable [92]. Variations in growth media, culture time, and presence of shear flow result in very different biofilm models, which drastically impact the results of a study. Several *in vitro* biofilm growth models have been developed to improve the clinical relevance of biofilms such as capillary flow cell bioreactors [93, 94], the Calgary Biofilm Device [95], microcarrier pebbles [92], or supplemented media [96]. However, there is no consensus yet on how to properly culture *S. aureus* biofilms. In our estimation, mouse models of implant-associated osteomyelitis are the most effective methods to mimic the *in vivo* biofilms that occur in the clinic [97, 98].

Osteocyte-lacuno canalicular network (OLCN) invasion

A newly discovered mechanism of immune evasion and persistence in chronic osteomyelitis is the invasion of the sub-micron channels deep within the cortical bone. Buried within the dense mineral matrix of bone are osteocytes, which are interconnected via canaliculi containing their cell processes. Their primary function is to maintain bone homeostasis by mechanotransduction [99]. In recent work, we have observed *S. aureus* invasion of the OLCN of bone by transmission electron microscopy [100]. Originally discovered in mouse models of implant-associated osteomyelitis, and later confirmed in a clinical case of diabetic foot infection, invasion of the OLCN appears to be a newly recognized mechanism of chronic bone infection [100**, 101**].

Staphylococcal invasion of the OLCN is particularly concerning for multiple reasons. First, *S. aureus* within the confined geometries of canaliculi or lacunae are completely protected from immune cell attack. Second, it is possible that the bacteria can survive for years by dissolving the surrounding bone mineral matrix as a source of nutrients. Finally, the depth of *S. aureus* invasion within the OLCN is not known but it could be a major factor in the failure of surgical debridement of infected bone.

It was shown that *S. aureus* is capable of colonizing and proliferating within the submicron canaliculi of bone, requiring them to deform as small as 0.2 μm in diameter. Further, BrdU immunoelectron microscopy was used to confirm that the bacterial cells at the leading edge of invasion are actively proliferating, as opposed to persisting in a dormant state. This finding was surprising given that *S. aureus* is a non-motile bacterium with no known mechanisms of active translocation. At this point, we hypothesized that *S. aureus* has a novel mechanism of invasion that enables asymmetric cell division into the opening of a canaliculus and onwards through the channel [100**].

In order to determine the mechanism of *S. aureus* invasion of the OLCN and to identify virulence genes responsible for haptotaxis and durotaxis, an in vitro model of canalicular invasion, named the $\mu\text{SiM-CA}$, has been developed [100**, 102]. Our recent work demonstrated that the *agr* quorum sensing system may not be necessary for propagation through 0.5 μm nanopores *in vitro* [102]. This result was confirmed in our mouse model of implant-associated osteomyelitis, where an *agr* deletion strain of *S. aureus* was capable of invading the sub-micron canalicular network of bone. Continued work using the $\mu\text{SiM-CA}$ is warranted to determine the genetic mechanism of *S. aureus* invasion of the OLCN.

Intracellular colonization of non-professional phagocytes

The final potential mechanism of *S. aureus* persistence in osteomyelitis is long-term intracellular infection. *S. aureus* is no longer defined as a strictly extracellular pathogen, and it is known that *S. aureus* can survive and proliferate within leukocytes during sepsis [79]. Numerous studies have documented internalization of *S. aureus* by non-professional phagocytes including epithelial cells [103], endothelial cells [104], keratinocytes [105], and fibroblasts [105] in a variety of infection settings. It is thought that *S. aureus* triggers internalization by FnBPA and FnBPB binding fibrinogen and bridging to $\alpha_5\beta_1$ integrins

[106]. Following internalization, the bacteria can evade cell death via persistence within vacuoles, endosomal escape, or by preventing phagolysosomal fusion [107].

Specifically, in the context of osteomyelitis, osteoblasts [108–110], osteoclasts [111] and osteocytes [112] have been extensively studied in vitro as possible reservoirs for intracellular colonization. Intracellular persistence, even for a short window of time, may provide the bacteria with a mechanism of immune cell evasion as well as protection from antibiotic treatments. It is hypothesized that in order to persist intracellularly, *S. aureus* adopts a slow-growing, metabolically inactive state like that of small colony variants (SCVs) [113]. Unfortunately, the majority of these studies were performed in vitro with little relevance to the dynamic host-pathogen interactions in vivo. Currently, very few in vivo or clinical studies have linked *S. aureus* intracellular infection with chronic osteomyelitis [114, 87, 30]. Thus, some crucial questions that remain unanswered are the length of time *S. aureus* can persist intracellularly in bone cells, and if intracellular *S. aureus* is a cause of recurrent osteomyelitis.

Conclusions

S. aureus osteomyelitis continues to be a major clinical problem and the bane of orthopaedic surgery. Elucidation of several *S. aureus* immune evasion mechanisms, and definition of its humoral immune proteome in osteomyelitis have markedly improved our understanding of chronic osteomyelitis over the past few decades. Moreover, the recent discovery of *S. aureus* invasion of the OLCN provides a clear explanation for why this form of bone infection is incurable. With this knowledge of the complex pathophysiology of *S. aureus* osteomyelitis, the current challenge is to translate this new information into novel tests and interventions to properly diagnose and treat the most common forms of bone infection.

Funding

GM is supported by grants from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) P30 AR069655 pilot and AO Trauma Research Fellowship (Davos, Switzerland). EMS is supported by grants from NIAMS P50 AR072000, P30 AR069655) and AOTrauma, Clinical Priority Program (Davos, Switzerland). JLD is supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) R21 AI119646.

References

Papers recently published and of particular interest have been highlighted as:

* Of interest,

** Of significant interest

1. Tande AJ, Patel R. Prosthetic joint infection. Clinical microbiology reviews. 2014;27(2):302–45. doi:10.1128/CMR.00111-13. [PubMed: 24696437]
2. Bryan AJ, Abdel MP, Sanders TL, Fitzgerald SF, Hanssen AD, Berry DJ. Irrigation and Debridement with Component Retention for Acute Infection After Hip Arthroplasty: Improved Results with Contemporary Management. J Bone Joint Surg Am. 2017;99(23):2011–8. doi:10.2106/JBJS.16.01103. [PubMed: 29206791]
3. Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sanchez-Somolinos M, Baraia-Etxaburu JM et al. A large multicenter study of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus* prosthetic joint infections managed with implant retention. Clinical infectious diseases : an

official publication of the Infectious Diseases Society of America. 2013;56(2):182–94. doi:10.1093/cid/cis746.

4. Nodzo SR, Boyle KK, Spiro S, Nocon AA, Miller AO, Westrich GH. Success rates, characteristics, and costs of articulating antibiotic spacers for total knee periprosthetic joint infection. *Knee*. 2017;24(5):1175–81. doi:10.1016/j.knee.2017.05.016. [PubMed: 28797875]
5. Kurtz SM, Ong KL, Schmier J, Mowat F, Saleh K, Dybvik E et al. Future clinical and economic impact of revision total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2007;89 Suppl 3:144–51. doi:10.2106/JBJS.G.00587. [PubMed: 17908880]
6. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am*. 2007;89(4):780–5. doi:10.2106/JBJS.F.00222. [PubMed: 17403800]
- * 7. Schwarz EM, Parvizi J, Gehrke T, Aiyer A, Battenberg A, Brown SA et al. 2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. *J Orthop Res*. 2019;37(5):997–1006. doi:10.1002/jor.24293. [PubMed: 30977537]
- * 8. Parvizi J, Gehrke T, Mont MA, Callaghan JJ. Introduction: Proceedings of International Consensus on Orthopedic Infections. *J Arthroplasty*. 2019;34(2S):S1–S2. doi:10.1016/j.arth.2018.09.038.
- * 9. Saeed K, McLaren AC, Schwarz EM, Antoci V, Arnold WV, Chen AF et al. 2018 international consensus meeting on musculoskeletal infection: Summary from the biofilm workgroup and consensus on biofilm related musculoskeletal infections. *J Orthop Res*. 2019;37(5):1007–17. doi:10.1002/jor.24229. [PubMed: 30667567] Manuscripts outlining important research priorities that were discussed in the 2018 International Consensus Meeting on Musculoskeletal Infection.
10. Kavanagh N, Ryan EJ, Widaa A, Sexton G, Fennell J, O'Rourke S et al. Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions. *Clinical microbiology reviews*. 2018;31(2). doi:10.1128/CMR.00084-17.
11. Lew DP, Waldvogel FA. Osteomyelitis. *Lancet*. 2004;364(9431):369–79. doi:10.1016/S0140-6736(04)16727-5. [PubMed: 15276398]
- * 12. Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, McFadyen I, Scarborough M et al. Fracture-related infection: A consensus on definition from an international expert group. *Injury*. 2018;49(3):505–10. doi:10.1016/j.injury.2017.08.040. [PubMed: 28867644] Manuscript attempting to solidify the clinical definition of “fracture-related infection” for the first time based on consensus from an international group of orthopaedic surgeons and researchers
13. Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med*. 2017;376(24):2367–75. doi:10.1056/NEJMr1615439. [PubMed: 28614678]
14. Gamain R, Coulomb R, Houzir K, Molinari N, Kouyoumdjian P, Lonjon N. Anterior cervical spine surgical site infection and pharyngoesophageal perforation. Ten-year incidence in 1475 patients. *Orthop Traumatol Surg Res*. 2019;105(4):697–702. doi:10.1016/j.otsr.2019.02.018. [PubMed: 30987954]
15. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. *Clin Orthop Relat Res*. 2008;466(7):1710–5. doi:10.1007/s11999-008-0209-4. [PubMed: 18421542]
16. Metsemakers WJ, Kuehl R, Moriarty TF, Richards RG, Verhofstad MHJ, Borens O et al. Infection after fracture fixation: Current surgical and microbiological concepts. *Injury*. 2018;49(3):511–22. doi:10.1016/j.injury.2016.09.019. [PubMed: 27639601]
17. Copley LA. Pediatric musculoskeletal infection: trends and antibiotic recommendations. *J Am Acad Orthop Surg*. 2009;17(10):618–26. [PubMed: 19794219]
18. Funk SS, Copley LA. Acute Hematogenous Osteomyelitis in Children: Pathogenesis, Diagnosis, and Treatment. *Orthop Clin North Am*. 2017;48(2):199–208. doi:10.1016/j.ocl.2016.12.007. [PubMed: 28336042]
19. Calhoun JH, Manring MM, Shirliff M. Osteomyelitis of the long bones. *Semin Plast Surg*. 2009;23(2):59–72. doi:10.1055/s-0029-1214158. [PubMed: 20567728]
20. Kak V, Chandrasekar PH. Bone and joint infections in injection drug users. *Infect Dis Clin North Am*. 2002;16(3):681–95. [PubMed: 12371122]

21. Skolnick P The Opioid Epidemic: Crisis and Solutions. *Annu Rev Pharmacol Toxicol*. 2018;58:143–59. doi:10.1146/annurev-pharmtox-010617-052534. [PubMed: 28968188]
22. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration? *J Am Podiatr Med Assoc*. 2008;98(6):489–93. [PubMed: 19017860]
23. Neville RF, Kayssi A, Buescher T, Stempel MS. The diabetic foot. *Curr Probl Surg*. 2016;53(9):408–37. doi:10.1067/j.cpsurg.2016.07.003. [PubMed: 27687301]
24. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. *Lancet*. 2005;366(9498):1719–24. doi:10.1016/S0140-6736(05)67698-2. [PubMed: 16291066]
25. Kaplan SL. Recent lessons for the management of bone and joint infections. *The Journal of infection*. 2014;68 Suppl 1:S51–6. doi:10.1016/j.jinf.2013.09.014. [PubMed: 24119927]
26. Teterycz D, Ferry T, Lew D, Stern R, Assal M, Hoffmeyer P et al. Outcome of orthopedic implant infections due to different staphylococci. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2010;14(10):e913–8. doi:10.1016/j.ijid.2010.05.014. [PubMed: 20729115]
27. Ogston A Report upon Micro-Organisms in Surgical Diseases. *Br Med J*. 1881;1(1054):369 b2–75.
28. Hemmady MV, Al-Maiyah M, Shoaib A, Morgan-Jones RL. Recurrence of chronic osteomyelitis in a regenerated fibula after 65 years. *Orthopedics*. 2007;30(5).
29. Gallie W First recurrence of osteomyelitis eighty years after infection. *The Journal of bone and joint surgery British volume*. 1951;33(1):110–1. [PubMed: 14814172]
30. Bosse MJ, Gruber HE, Ramp WK. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis: a case report. *JBJS*. 2005;87(6):1343–7.
31. Libraty DH, Patkar C, Torres B. Staphylococcus aureus reactivation osteomyelitis after 75 years. *New England Journal of Medicine*. 2012;366(5):481–2. [PubMed: 22296093]
- ** 32. Broker BM, Mrochen D, Peton V. The T Cell Response to Staphylococcus aureus. *Pathogens*. 2016;5(1). doi:10.3390/pathogens5010031. An excellent review that summarizes S. aureus - specific T cell response in disease and colonization
33. O'Brien EC, McLoughlin RM. Considering the 'Alternatives' for Next-Generation Anti-Staphylococcus aureus Vaccine Development. *Trends Mol Med*. 2019;25(3):171–84. doi:10.1016/j.molmed.2018.12.010. [PubMed: 30713007]
34. Seebach E, Kubatzky KF. Chronic Implant-Related Bone Infections—Can Immune Modulation be a Therapeutic Strategy? *Front Immunol*. 2019;10(1724). doi:10.3389/fimmu.2019.01724.
35. Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, Uhlen M. Staphylococcal protein A consists of five IgG-binding domains. *Eur J Biochem*. 1986;156(3):637–43. [PubMed: 2938951]
36. Cedergren L, Andersson R, Jansson B, Uhlen M, Nilsson B. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. *Protein Eng*. 1993;6(4):441–8. [PubMed: 8332602]
37. Schneewind O, Model P, Fischetti VA. Sorting of protein A to the staphylococcal cell wall. *Cell*. 1992;70(2):267–81. doi:10.1016/0092-8674(92)90101-h. [PubMed: 1638631]
38. Graille M, Stura EA, Corper AL, Sutton BJ, Taussig MJ, Charbonnier JB et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. *Proceedings of the National Academy of Sciences of the United States of America*. 2000;97(10):5399–404. doi:10.1073/pnas.97.10.5399. [PubMed: 10805799]
39. Goodyear CS, Silverman GJ. Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal Toxin. *J Exp Med*. 2003;197(9):1125–39. doi:10.1084/jem.20020552. [PubMed: 12719481]
40. Pauli NT, Kim HK, Falugi F, Huang M, Dulac J, Henry Dunand C et al. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. *J Exp Med*. 2014;211(12):2331–9. doi:10.1084/jem.20141404. [PubMed: 25348152]
41. Keener AB, Thurlow LT, Kang S, Spidale NA, Clarke SH, Cunnion KM et al. Staphylococcus aureus Protein A Disrupts Immunity Mediated by Long-Lived Plasma Cells. *J Immunol*. 2017;198(3):1263–73. doi:10.4049/jimmunol.1600093. [PubMed: 28031339]

- * 42. Falugi F, Kim HK, Missiakas DM, Schneewind O. Role of protein A in the evasion of host adaptive immune responses by *Staphylococcus aureus*. *mBio*. 2013;4(5):e00575–13. doi:10.1128/mBio.00575-13. [PubMed: 23982075] This study describes the key role of protein A in the pathogenesis of staphylococcal infections
43. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. Nontoxic protein A vaccine for methicillin-resistant *Staphylococcus aureus* infections in mice. *J Exp Med*. 2010;207(9):1863–70. doi:10.1084/jem.20092514. [PubMed: 20713595]
44. Thammavongsa V, Rauch S, Kim HK, Missiakas DM, Schneewind O. Protein A-neutralizing monoclonal antibody protects neonatal mice against *Staphylococcus aureus*. *Vaccine*. 2015;33(4):523–6. doi:10.1016/j.vaccine.2014.11.051. [PubMed: 25488332]
45. Kim HK, Falugi F, Thomer L, Missiakas DM, Schneewind O. Protein A suppresses immune responses during *Staphylococcus aureus* bloodstream infection in guinea pigs. *mBio*. 2015;6(1). doi:10.1128/mBio.02369-14.
46. Chen X, Sun Y, Missiakas D, Schneewind O. *Staphylococcus aureus* Decolonization of Mice With Monoclonal Antibody Neutralizing Protein A. *The Journal of infectious diseases*. 2019;219(6):884–8. doi:10.1093/infdis/jiy597. [PubMed: 30551184]
47. Nygaard TK, Kobayashi SD, Freedman B, Porter AR, Voyich JM, Otto M et al. Interaction of *Staphylococci* with Human B cells. *PLoS One*. 2016;11(10):e0164410. doi:10.1371/journal.pone.0164410. [PubMed: 27711145]
48. Garcia BL, Ramyar KX, Ricklin D, Lambris JD, Geisbrecht BV. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of *Staphylococcal* immune evasion proteins. *Adv Exp Med Biol*. 2012;946:113–33. doi:10.1007/978-1-4614-0106-3_7. [PubMed: 21948365]
- ** 49. Nishitani K, Beck CA, Rosenberg AF, Kates SL, Schwarz EM, Daiss JL. A Diagnostic Serum Antibody Test for Patients With *Staphylococcus aureus* Osteomyelitis. *Clin Orthop Relat Res*. 2015;473(9):2735–49. doi:10.1007/s11999-015-4354-2. [PubMed: 26013151] The first Luminex-based immunoassay in blood serum to detect *S. aureus* osteomyelitis in patients
50. Holtfreter S, Kolata J, Broker BM. Towards the immune proteome of *Staphylococcus aureus* - The anti-*S. aureus* antibody response. *Int J Med Microbiol*. 2010;300(2–3):176–92. doi:10.1016/j.ijmm.2009.10.002. [PubMed: 19889576]
51. van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W, Vos MC et al. Co-evolutionary aspects of human colonisation and infection by *Staphylococcus aureus*. *Infect Genet Evol*. 2009;9(1):32–47. [PubMed: 19000784]
52. Stentzel S, Sundaramoorthy N, Michalik S, Nordengrun M, Schulz S, Kolata J et al. Specific serum IgG at diagnosis of *Staphylococcus aureus* bloodstream invasion is correlated with disease progression. *J Proteomics*. 2015;128:1–7. doi:10.1016/j.jprot.2015.06.018. [PubMed: 26155744]
53. Verkaik NJ, Boelens HA, de Vogel CP, Tavakol M, Bode LG, Verbrugh HA et al. Heterogeneity of the humoral immune response following *Staphylococcus aureus* bacteremia. *Eur J Clin Microbiol Infect Dis*. 2010;29(5):509–18. doi:10.1007/s10096-010-0888-0. [PubMed: 20186449]
54. den Reijer PM, Lemmens-den Toom N, Kant S, Sijnders SV, Boelens H, Tavakol M et al. Characterization of the humoral immune response during *Staphylococcus aureus* bacteremia and global gene expression by *Staphylococcus aureus* in human blood. *PLoS One*. 2013;8(1):e53391. doi:10.1371/journal.pone.0053391. [PubMed: 23308212]
55. Gedbjerg N, LaRosa R, Hunter JG, Varrone JJ, Kates SL, Schwarz EM et al. Anti-glucosaminidase IgG in sera as a biomarker of host immunity against *Staphylococcus aureus* in orthopaedic surgery patients. *J Bone Joint Surg Am*. 2013;95(22):e171. doi:10.2106/JBJS.L.01654. [PubMed: 24257671]
56. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW et al. Effect of an investigational vaccine for preventing *Staphylococcus aureus* infections after cardiothoracic surgery: a randomized trial. *JAMA*. 2013;309(13):1368–78. doi:10.1001/jama.2013.3010. [PubMed: 23549582]
57. Varrone JJ, Li D, Daiss JL, Schwarz EM. Anti-Glucosaminidase Monoclonal Antibodies as a Passive Immunization for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Orthopaedic Infections. *Bonekey Osteovision*. 2011;8:187–94. doi:10.1138/20110506. [PubMed: 22328866]

- * 58. Varrone JJ, de Mesy Bentley KL, Bello-Irizarry SN, Nishitani K, Mack S, Hunter JG et al. Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of *Staphylococcus aureus* megaclusters. *J Orthop Res*. 2014;32(10):1389–96. doi:10.1002/jor.22672. [PubMed: 24992290] This study describes a potential passive vaccination strategy to control *S. aureus* infection of the bone
59. Ghasemzadeh-Moghaddam H, van Wamel W, van Belkum A, Hamat RA, Tavakol M, Neela VK. Humoral immune consequences of *Staphylococcus aureus* ST239-associated bacteremia. *Eur J Clin Microbiol Infect Dis*. 2018;37(2):255–63. doi:10.1007/s10096-017-3124-3. [PubMed: 29103153]
60. Wu Y, Liu X, Akhgar A, Li JJ, Mok H, Sellman BR et al. Prevalence of IgG and Neutralizing Antibodies against *Staphylococcus aureus* Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations. *Infection and immunity*. 2018;86(3). doi:10.1128/IAI.00671-17.
61. Rigat F, Bartolini E, Dalsass M, Kumar N, Marchi S, Speziale P et al. Retrospective Identification of a Broad IgG Repertoire Differentiating Patients With *S. aureus* Skin and Soft Tissue Infections From Controls. *Front Immunol*. 2019;10:114. doi:10.3389/fimmu.2019.00114. [PubMed: 30792711]
- * 62. Carter MJ, Mitchell RM, Meyer Sauter PM, Kelly DF, Truck J. The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications. *Front Immunol*. 2017;8:630. doi:10.3389/fimmu.2017.00630. [PubMed: 28620385] An excellent review on antibody-secreting cell response to infection
63. Lee FE, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. *The Journal of infectious diseases*. 2010;202(11):1659–66. doi:10.1086/657158. [PubMed: 20979459]
64. Lee FE, Halliley JL, Walsh EE, Moscattello AP, Kmush BL, Falsey AR et al. Circulating human antibody-secreting cells during vaccinations and respiratory viral infections are characterized by high specificity and lack of bystander effect. *J Immunol*. 2011;186(9):5514–21. doi:10.4049/jimmunol.1002932. [PubMed: 21441455]
65. Radke EE, Brown SM, Pelzek AJ, Fulmer Y, Hernandez DN, Torres VJ et al. Hierarchy of human IgG recognition within the *Staphylococcus aureus* immunome. *Sci Rep*. 2018;8(1):13296. doi:10.1038/s41598-018-31424-3. [PubMed: 30185867]
66. Raqib R, Mondal D, Karim MA, Chowdhury F, Ahmed S, Luby S et al. Detection of antibodies secreted from circulating *Mycobacterium tuberculosis*-specific plasma cells in the diagnosis of pediatric tuberculosis. *Clin Vaccine Immunol*. 2009;16(4):521–7. doi:10.1128/CI.00391-08. [PubMed: 19193833]
67. Kyu SY, Kobie J, Yang H, Zand MS, Topham DJ, Quataert SA et al. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells. *J Immunol Methods*. 2009;340(1):42–7. doi:10.1016/j.jim.2008.09.025. [PubMed: 18996127]
- ** 68. Oh I, Muthukrishnan G, Ninomiya MJ, Brodell JD Jr., Smith BL, Lee CC et al. Tracking Anti-*Staphylococcus aureus* Antibodies Produced In Vivo and Ex Vivo during Foot Salvage Therapy for Diabetic Foot Infections Reveals Prognostic Insights and Evidence of Diversified Humoral Immunity. *Infection and immunity*. 2018;86(12). doi:10.1128/IAI.00629-18. First study to describe the utility of antibodies secreted by circulating plasmablasts as a diagnostic and prognostic tool to identify *S. aureus* diabetic foot infections.
69. Cheng AG, DeDent AC, Schneewind O, Missiakas D. A play in four acts: *Staphylococcus aureus* abscess formation. *Trends in microbiology*. 2011;19(5):225–32. [PubMed: 21353779]
70. McDevitt D, Francois P, Vaudaux P, Foster T. Molecular characterization of the clumping factor (fibrinogen receptor) of *Staphylococcus aureus*. *Molecular microbiology*. 1994;11(2):237–48. [PubMed: 8170386]
71. Higgins J, Loughman A, Van Kessel KP, Van Strijp JA, Foster TJ. Clumping factor A of *Staphylococcus aureus* inhibits phagocytosis by human polymorphonuclear leucocytes. *FEMS microbiology letters*. 2006;258(2):290–6. [PubMed: 16640587]

72. Postma B, Poppelier MJ, Van Galen JC, Prossnitz ER, Van Strijp JA, De Haas CJ et al. Chemotaxis inhibitory protein of *Staphylococcus aureus* binds specifically to the C5a and formylated peptide receptor. *The Journal of Immunology*. 2004;172(11):6994–7001. [PubMed: 15153520]
73. Rooijackers SH, Ruyken M, Van Roon J, Van Kessel KP, Van Strijp JA, Van Wamel WJ. Early expression of SCIN and CHIPS drives instant immune evasion by *Staphylococcus aureus*. *Cellular microbiology*. 2006;8(8):1282–93. [PubMed: 16882032]
74. Hammer ND, Skaar EP. Molecular mechanisms of *Staphylococcus aureus* iron acquisition. *Annual review of microbiology*. 2011;65:129–47.
75. Kim HK, DeDent A, Cheng AG, McAdow M, Bagnoli F, Missiakas DM et al. IsdA and IsdB antibodies protect mice against *Staphylococcus aureus* abscess formation and lethal challenge. *Vaccine*. 2010;28(38):6382–92. [PubMed: 20226248]
76. Cheng AG, Kim HK, Burts ML, Krausz T, Schneewind O, Missiakas DM. Genetic requirements for *Staphylococcus aureus* abscess formation and persistence in host tissues. *The FASEB Journal*. 2009;23(10):3393–404. [PubMed: 19525403]
77. Viana D, Blanco J, Tormo-Más MÁ, Selva L, Guinane CM, Baselga R et al. Adaptation of *Staphylococcus aureus* to ruminant and equine hosts involves SaPI-carried variants of von Willebrand factor-binding protein. *Molecular microbiology*. 2010;77(6):1583–94. [PubMed: 20860091]
78. Burts ML, DeDent AC, Missiakas DM. EsaC substrate for the ESAT-6 secretion pathway and its role in persistent infections of *Staphylococcus aureus*. *Molecular microbiology*. 2008;69(3):736–46. [PubMed: 18554323]
- * 79. Masters EA, Trombetta RP, de Mesy Bentley KL, Boyce BF, Gill AL, Gill SR et al. Evolving concepts in bone infection: redefining “biofilm”, “acute vs. chronic osteomyelitis”, “the immune proteome” and “local antibiotic therapy”. *Bone Research*. 2019;7(1):20. doi:10.1038/s41413-019-0061-z. [PubMed: 31646012] A great review summarizing recent advances related to bone infection and antibiotic therapeutic strategies to tackle osteomyelitis
80. Farnsworth CW, Schott EM, Jensen SE, Zukoski J, Benvie AM, Refaai MA et al. Adaptive upregulation of Clumping Factor A (ClfA) by *S. aureus* in the obese, type 2 diabetic host mediates increased virulence. *Infection and immunity*. 2017;IAI. 01005–16.
81. Cassat JE, Hammer ND, Campbell JP, Benson MA, Perrien DS, Mrak LN et al. A secreted bacterial protease tailors the *Staphylococcus aureus* virulence repertoire to modulate bone remodeling during osteomyelitis. *Cell host & microbe*. 2013;13(6):759–72. [PubMed: 23768499]
82. Scherr TD, Heim CE, Morrison JM, Kielian T. Hiding in plain sight: interplay between staphylococcal biofilms and host immunity. *Frontiers in immunology*. 2014;5:37. [PubMed: 24550921]
83. Stoodley P, Nistico L, Johnson S, Lasko L-A, Baratz M, Gahlot V et al. Direct demonstration of viable *Staphylococcus aureus* biofilms in an infected total joint arthroplasty: a case report. *The Journal of Bone and Joint Surgery American volume*. 2008;90(8):1751. [PubMed: 18676908]
84. Flemming H-C, Wingender J. The biofilm matrix. *Nature Reviews Microbiology*. 2010;8(9):623–33. [PubMed: 20676145]
85. Mah T-FC, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. *Trends in microbiology*. 2001;9(1):34–9. [PubMed: 11166241]
86. Proctor RA, Von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nature Reviews Microbiology*. 2006;4(4):295. [PubMed: 16541137]
87. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. *Staphylococcus aureus* small colony variants in prosthetic joint infection. *Clinical infectious diseases*. 2006;43(8):961–7. [PubMed: 16983605]
88. Gillaspay AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. *Infection and immunity*. 1995;63(9):3373–80. [PubMed: 7642265]
89. Salam AM, Quave CL. Targeting virulence in *Staphylococcus aureus* by chemical inhibition of the accessory gene regulator system in vivo. *MSphere*. 2018;3(1):e00500–17. [PubMed: 29359191]

90. Ricciardi BF, Muthukrishnan G, Masters E, Ninomiya M, Lee CC, Schwarz EM. Staphylococcus aureus Evasion of Host Immunity in the Setting of Prosthetic Joint Infection: Biofilm and Beyond. *Curr Rev Musculoskelet Med*. 2018. doi:10.1007/s12178-018-9501-4.
91. Paharik AE, Horswill AR. The Staphylococcal Biofilm: Adhesins, Regulation, and Host Response. *Microbiol Spectr*. 2016;4(2). doi:10.1128/microbiolspec.VMBF-0022-2015.
92. Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S et al. Gene expression in *Pseudomonas aeruginosa* biofilms. *Nature*. 2001;413(6858):860–4. [PubMed: 11677611]
93. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S et al. Stratified growth in *Pseudomonas aeruginosa* biofilms. *Applied and environmental microbiology*. 2004;70(10):6188–96. [PubMed: 15466566]
94. Deligianni E, Pattison S, Berrar D, Ternan NG, Haylock RW, Moore JE et al. *Pseudomonas aeruginosa* cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro. *BMC microbiology*. 2010;10(1):38. [PubMed: 20141637]
95. Ceri H, Olson M, Stremick C, Read R, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. *Journal of clinical microbiology*. 1999;37(6):1771–6. [PubMed: 10325322]
96. Yang L, Haagenen JA, Jelsbak L, Johansen HK, Sternberg C, Høiby N et al. In situ growth rates and biofilm development of *Pseudomonas aeruginosa* populations in chronic lung infections. *Journal of bacteriology*. 2008;190(8):2767–76. [PubMed: 18156255]
97. Reizner W, Hunter J, O'Malley N, Southgate R, Schwarz E, Kates S. A systematic review of animal models for *Staphylococcus aureus* osteomyelitis. *European cells & materials*. 2014;27:196. [PubMed: 24668594]
98. Nishitani K, Sutipornpalangkul W, de Mesy Bentley KL, Varrone JJ, Bello-Irizarry SN, Ito H et al. Quantifying the natural history of biofilm formation in vivo during the establishment of chronic implant-associated *Staphylococcus aureus* osteomyelitis in mice to identify critical pathogen and host factors. *Journal of Orthopaedic Research*. 2015;33(9):1311–9. [PubMed: 25820925]
99. Burger EH, Klein-Nulend J. Mechanotransduction in bone—role of the lacuno-canalicular network. *The FASEB Journal*. 1999;13(9001):S101–S12. [PubMed: 10352151]
- ** 100. de Mesy Bentley KL, Trombetta R, Nishitani K, Bello-Irizarry SN, Ninomiya M, Zhang L et al. Evidence of *Staphylococcus Aureus* Deformation, Proliferation, and Migration in Canaliculi of Live Cortical Bone in Murine Models of Osteomyelitis. *J Bone Miner Res*. 2017;32(5):985–90. doi:10.1002/jbmr.3055. [PubMed: 27933662]
- ** 101. de Mesy Bentley KL, MacDonald A, Schwarz EM, Oh I. Chronic Osteomyelitis with *Staphylococcus aureus* Deformation in Submicron Canaliculi of Osteocytes: A Case Report. *JBJS Case Connect*. 2018. doi:10.2106/JBJS.CC.17.00154. Murine and human In vivo evidence demonstrating that *S. aureus* can enter and proliferate in the submicron canilicular space deep within the bone
102. Elysia A Masters ATS, Stefano Begolo, Emma N Luke, Sydney C Barrett, Clyde T Overby, Ann Lindley Gill, Karen L de Mesy Bentley, Hani A Awad, Steven R Gill, Edward M Schwarz, and James L McGrath An in vitro platform for elucidating the molecular genetics of *S. aureus* invasion of the osteocyte lacuno-canalicular network during chronic osteomyelitis *Nanomedicine: nanotechnology, biology and medicine*. 2019. doi:10.1016/j.nano.2019.102039.
103. Malouin F, Brouillette E, Martinez A, Boyll BJ, Toth JL, Gage JL et al. Identification of antimicrobial compounds active against intracellular *Staphylococcus aureus*. *FEMS Immunology & Medical Microbiology*. 2005;45(2):245–52. [PubMed: 15963705]
104. Vesga O, Groeschel MC, Otten MF, Brar DW, Vann JM, Proctor RA. *Staphylococcus aureus* small colony variants are induced by the endothelial cell intracellular milieu. *Journal of Infectious Diseases*. 1996;173(3):739–42. [PubMed: 8627043]
105. Krut O, Sommer H, Krönke M. Antibiotic-induced persistence of cytotoxic *Staphylococcus aureus* in non-phagocytic cells. *Journal of Antimicrobial Chemotherapy*. 2004;53(2):167–73. [PubMed: 14729736]
106. Edwards AM, Potts JR, Josefsson E, Massey RC. *Staphylococcus aureus* host cell invasion and virulence in sepsis is facilitated by the multiple repeats within FnBPA. *PLoS pathogens*. 2010;6(6):e1000964. [PubMed: 20585570]

107. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends in microbiology. 2009;17(2):59–65. [PubMed: 19208480]
108. Reott MA Jr, Ritchie-Miller SL, Anguita J, Hudson MC. TRAIL expression is induced in both osteoblasts containing intracellular Staphylococcus aureus and uninfected osteoblasts in infected cultures. FEMS microbiology letters. 2008;278(2):185–92. [PubMed: 18070069]
109. Mohamed W, Sommer U, Sethi S, Domann E, Thormann U, Schutz I et al. Intracellular proliferation of S. aureus in osteoblasts and effects of rifampicin and gentamicin on S. aureus intracellular proliferation and survival. Eur Cell Mater. 2014;28:258–68. [PubMed: 25340805]
110. Ellington JK, Elhofy A, Bost KL, Hudson MC. Involvement of mitogen-activated protein kinase pathways in Staphylococcus aureus invasion of normal osteoblasts. Infection and immunity. 2001;69(9):5235–42. [PubMed: 11500391]
111. Klenerman L A history of osteomyelitis from the Journal of Bone and Joint Surgery: 1948 to 2006. The Journal of bone and joint surgery British volume. 2007;89(5):667–70. [PubMed: 17540756]
112. Yang D, Wijenayaka AR, Solomon LB, Pederson SM, Findlay DM, Kidd SP et al. Novel Insights into Staphylococcus aureus Deep Bone Infections: the Involvement of Osteocytes. mBio. 2018;9(2):e00415–18. [PubMed: 29691335]
113. Tuchscher L, Heitmann V, Hussain M, Viemann D, Roth J, von Eiff C et al. Staphylococcus aureus small-colony variants are adapted phenotypes for intracellular persistence. The Journal of infectious diseases. 2010;202(7):1031–40. [PubMed: 20715929]
114. Reilly S, Hudson M, Kellam J, Ramp W. In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts. Bone. 2000;26(1):63–70. [PubMed: 10617158]

Figure 1: “Four Acts” of immune evasion and bacterial persistence during *S. aureus* osteomyelitis.

S. aureus in the bone environment is presented with several immune challenges. Four important immune mechanisms of *S. aureus* persistence in the context of osteomyelitis are: 1) abscesses formation; 2) biofilm formation; 3) invasion of the osteocyte-lacuno canalicular network (OLCN) of bone; and 4) intracellular colonization. **A)** *S. aureus* hijacks the host-induced abscess formation process to create an abscess with protected bacterial cells at its core, which are inaccessible to immune cell infiltration. *S. aureus* deploys numerous cell-wall associated and secreted virulence proteins to trigger the formation of this multilayered structure. **B)** Necrotic bone or metal implants are ideally suited for *S. aureus* biofilm formation. As illustrated, the process of biofilm development involves bacterial colonization/attachment, maturation, detachment, and dissemination. Dozens of MSCRAMMs, and virulence molecules such as Ica, PSMs play critical roles in this process. These factors are regulated by *agr* quorum-sensing system. **C)** A recently uncovered mechanism of chronic bacterial persistence is the invasion of the sub-micron channels deep within the cortical bone. Electron microscopy analyses of infected necrotic bone revealed the presence of *S. aureus*, which usually is a micron in diameter, in these sub-micron channels. Several surface adhesins, cell wall synthesis proteins, and cell division enzymes are hypothesized, but not yet confirmed, to play significant roles in OCLN invasion. **D)** Several in vitro, but not in vivo, studies have also demonstrated that *S. aureus* can survive intracellularly in non-

professional phagocytes such as osteoblasts, osteoclasts, and osteocytes during osteomyelitis. Specific proteins involved in this process of internalization have yet to be fully deciphered. It is also believed that in all the aforementioned mechanisms, *S. aureus* can also transform into a quasi-dormant small colony variant (SCV, illustrated as red bacteria) and persist in the bone for long periods of time.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript